PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Institute for Virology and Immunobiology, Julius-Maximilians-University Würzburg, 97078 Würzburg, Germany.\', \'Helmholtz-Institute for RNA-Based Infection Research, 97080 Würzburg, Germany.\', \'Department of Tropical Medicine, Klinikum Würzburg Mitte, 97074 Würzburg, Germany.\', \'Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Department of Internal Medicine II, 81675 Munich, Germany.\', \'German Center for Infection Research (DZIF), Partner Site Munich, Germany.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 96310.3390/v13060963
?:hasPublicationType
?:journal
  • Viruses
is ?:pmid of
?:pmid
?:pmid
  • 34067381
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.805
?:rankingScore_hIndex
  • 52
?:title
  • Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset-Lessons Learned.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34067381>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34067381>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all